SPARC seeks US nod for two drugs from alternative site
SunPharma'sresearcharm willinitiatesitetransferforits anti-epilepsydrugElepsia andeye-dropXelprosafter failingtoreceiveproduct approvalfromtheUSdrug regulator. Boththeproducts werefiledfromSunPharma's Halolplant, whichreceivedUS FoodandDrug Administration’swarningletter in2015. Assuch, thetwo productsdidnotreceive approval. SunPharma AdvancedResearchCompany (SPARC) nowplanstore-submit itsapplicationforproduct approvaltotheregulatorfrom analternativesite, chief executiveAnilRaghavansaid onThursday.